CJC-1295 (No DAC / Mod GRF 1-29) – User Manual & Dosage Protocol Guide

CJC-1295 (No DAC), also known as Mod GRF 1-29, is a short-acting synthetic analog of growth hormone-releasing hormone (GHRH) studied for its ability to stimulate pulsatile endogenous growth hormone (GH) secretion in research settings.

Unlike the DAC-modified version, this variant has a significantly shorter half-life and is typically used in pulse-based research protocols.

Research Applications

• GH pulsatility studies
• IGF-1 modulation research
• Body composition investigations
• Recovery and performance physiology models
• Sleep cycle and endocrine rhythm research

Disclaimer: CJC-1295 (No DAC) is for research and experimental use only and is not FDA-approved for general therapeutic use in this context.

Lyophilized Powder

Freeze-dried CJC-1295 (No DAC) designed for reconstitution before use in research settings.

Reconstituted Solution

Prepared liquid form used for subcutaneous research injection after proper reconstitution.

CJC-1295 (No DAC) is studied for its ability to:

• Bind GHRH receptors in the anterior pituitary
• Stimulate physiologic GH pulse release
• Increase downstream IGF-1 production
• Mimic natural GH pulsatility patterns due to short half-life

Because it lacks DAC modification, its activity window is brief, making it suitable for timed pulse research models.

Effects are primarily observed in investigational protocols.

Subcutaneous (SC) – Standard Research Model

Common research protocols use 100–300 mcg per administration, typically 1–3 times daily. It is often paired with GHS compounds in pulse-based models.

Higher-Range Research

Some studies use 300–500 mcg per administration, generally 1–2 times daily, when observing stronger GH-response patterns.

Administration Method

Most research protocols utilize subcutaneous (SC) administration for controlled and consistent delivery.

Research Note

Because of its short activity duration, many protocols use multiple daily administrations to maintain pulse-based growth hormone response in research settings.

Important

There is no approved dosage outside regulated clinical use. The ranges above reflect common research patterns only.

Initiation

A short 1–2 week phase used to evaluate growth hormone response and overall tolerance.

Active Study Phase

The 8–12 week primary phase focused on observing IGF-1 levels and body composition changes.

Extended Model

An optional phase up to 16 weeks for longer-term endocrine rhythm research.

Rest Period

A 2–4 week break between cycles to allow physiological systems to reset.

Note

Cycle length may vary depending on the specific study goals and research endpoints.

Supplies

• Sterile bacteriostatic water
• Sterile syringe
• Alcohol swabs

General Procedure

1. Clean vial stopper with alcohol.
2. Add bacteriostatic water to desired concentration.

• Example: 2 mg vial + 2 mL → 1 mg/mL

1. Swirl gently to dissolve (do not shake).
2. Refrigerate at 2–8°C after reconstitution.
3. Use within 2–4 weeks or per research protocol.

Avoid excessive agitation to preserve peptide stability.

Subcutaneous Injection Model

• Common sites: abdomen, thigh, upper arm
• Clean site prior to administration
• Inject slowly
• Rotate injection sites

Pulse-timing models often schedule administration around fasting periods or pre-sleep windows in research designs.

Lyophilized Powder

Store in a cool, dry environment to maintain stability and effectiveness.

Reconstituted Solution

Keep refrigerated at 2–8°C and use within 2–4 weeks after preparation.

Protection Guidelines

Protect from light, heat, and contamination to preserve quality.

Safety Note

Discard the solution if it becomes cloudy or discolored, as this may indicate contamination or degradation.

• Research use only
• Not for therapeutic application
• Human safety outside controlled research is not established
• Possible research observations may include:
• Injection-site irritation
• Headache
• Temporary flushing
• Mild water retention (GH-axis related)

Monitoring of IGF-1 and metabolic markers is common in investigational protocols.

Maintain sterile technique at all times.

Keep out of reach of children.

Peptide: CJC-1295 (No DAC / Mod GRF 1-29)
Category: Growth Hormone Axis / Short-Acting GHRH Research
Delivery: Subcutaneous research model
Typical Investigational Range: 100–500 mcg, 1–3 times daily
Cycle: 8–12 week research designs
Storage: Refrigerated after reconstitution